Executive Chairman
Acurx Pharmaceuticals, Inc.
White Plains, NY, United States
Bob DeLuccia; currently Executive Chairman of Acurx Pharmaceuticals. He has over 50 years’ executive and hands-on experience in the pharmaceutical industry involving sales, marketing, manufacturing and new product development with global pharmaceutical companies (Pfizer and Sanofi). Mr. DeLuccia has held senior executive positions in both companies and has also been Chief Executive Officer of two publicly traded (Nasdaq) biopharmaceutical companies (Immunomedics, Inc. and MacroChem CORP). He was formerly Executive Chairman of publicly-traded (Nasdaq) Dipexium Pharmaceuticals, Inc., a New York-based, antibiotic development-stage biopharmaceutical company which he Co-Founded and subsequently took public. His therapeutic areas of marketing experience include new product introductions and drug development in the following areas: antibiotics (doxycycline, bacampicillin, cefaperazone) and antidiabetic agents (chlorpropamide and glypizide); and cardiovasculars (prazosin, amrinone; clopidogrel) and iohexol contrast media. New drug development areas included: topical creams/gels for erectile dysfunction, testosterone, onychomycosis and diabetic foot infection.
Michael Silverman, MD,FACP, Medical Director, Acurx Pharmaceuticals. He is a Board-certified internist with over 3 decades of experience in biopharmaceutical industry clinical research, product development, and strategic planning across a broad scope of therapeutic areas. He has
extensive experience in pharmaceutical clinical development and management, and is the principal of BioStrategics Consulting which provides strategic and technical clinical development consulting services to development-stage biotechnology and pharmaceutical companies around the world.
Disclosure(s): No financial relationships to disclose
28 - Novel DNA pol IIIC Inhibitors for Gram-positive Bacterial Infections
Thursday, October 12, 2023
8:00 AM – 8:12 AM US ET